RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > A Review of the Pharmacovigilance Programme of India

A Review of the Pharmacovigilance Programme of India

Posted 01 September 2011

Over the past decade, India has been steadily evolving into one of the world's most important pharmaceutical centers for clinical trials and research and development. With success has come the burden of growing pressure on the Indian government to address concerns related to establishing a reliable drug safety framework.

 

© 2022 Regulatory Affairs Professionals Society.